Angioedema

Type: Keyphrase

Name: Angioedema

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Angioedema Partnering 2007-2013

Research and Markets (http://www.researchandmarkets.com/research/7tjkwg/angioedema) has announced the addition of the " " report to their offering. Angioedema Partnering 2007-2013 report provides understanding and access to the angioedema partnering deals ... [Published Individual.com - May 21 2013]

Entities: Angioedema, International Market, Due Diligence

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Natural Urticaria & Angioedema Treatment Review - Effective Ways to Cure Urticaria and Angioedema Has Been Reviewed

Denver, CO -- ( SBWIRE ) -- 05/15/2013 -- The official Natural Urticaria & Angioedema Treatment review right here has been created with the sole purpose of helping people all around the world analyze all the details concerning urticaria and Angioedema ... [Published SBWire - May 15 2013]

Entities: Angioedema, Urticaria, John Colston, Integrity, Immune System

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Fresh Frozen Plasma for ACEI-Induced Angioedema

Is fresh frozen plasma a safe and effective alternative treatment option for ACEI-induced angioedema?The Journal of Emergency Medicine ... [Published Medscape - May 06 2013]

Entities: Fresh Frozen Plasma, Angioedema, Emergency Medicine

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Health Article - Angioedema (Giant Hives): Overview, Causes & Symptoms

Angioedema is severe swelling beneath the skin. The swelling may also occur on the surface of the skin. In some cases, the swelling is combined with the appearance of hives. Some areas of the body such as the face and limbs, are more prone to swelling ... [Published AARP - Segunda Juventud - Apr 19 2013]

Entities: Angioedema, Urticaria, Hereditary Angioedema

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Santarus Inc

Santarus Stock Climbs Slightly After Submitting Drug Marketing Application to FDA

Company stock rose marginally after San Diego-based Santarus Inc. announced it submitted an application to the U.S. Food and Drug Administration for the marketing approval of its drug Ruconest.At market close the company’s shares were trading at $18.98 ... [Published San Diego Business Journal - Apr 18 2013]

Entities: Santarus Inc, Ruconest, Drugs

First reported Apr 16 2013 - Updated Apr 16 2013 - 1 reports

Hereditary and acquired angioedemas: rare but potentially life-threatening

Angioedema without urticaria should prompt consideration of hereditary, or acquired, C1 inhibitor deficiency-associated and ACE inhibitor-induced angioedema. These rare forms require different management to urticaria-associated angioedema as they do not ... [Published Medicine Today - Apr 16 2013]

Entities: Urticaria, Angioedema, Hereditary Angioedema

Quotes

"The pooled analyses represent an important body of evidence supporting MYRBETRIQ as a potential treatment option for OAB symptoms of urge urinary incontinence, urgency and urinary frequency" said Shontelle Dodson, PharmD, Senior Director, Astellas Scientific and Medical Affairs

Data on MYRBETRIQ (mirabegron) as Treatment for Overactive Bladder Presented at AUA 2013 [Published FinanzNachrichten.de - May 07 2013]

...Revlimid to patients with MDS throughout the EU who have an isolated del(5q) cytogenic abnormality," said Alan Colowick, President of Celgene EMEA. "Following the final decision by the European Commission within the next few months, we can begin the work of partnering with our many stakeholders to ensure patients have access to this new treatment option."

Celgene International Sarl Reports European Medicines Agency's Opinion for Revlimid [Published Individual.com - May 01 2013]

...can have a significant impact on patients and can be challenging to manage," said Tim Wright, Global Head of Development, Novartis Pharmaceuticals. "We are committed to helping patients with this disease and look forward to receiving further results from ongoing longer-term clinical trials."

Novartis' ASTERIA II stuy shows omalizumab improves itch in patients with chronic form of hives w ... [Published PharmaBiz - Feb 26 2013]

More Content

sort by: Date \| Relevance
Research and Markets: Angioedema Partnering 200... [Published Business Wire Professional Services News - May 21 2013]
Angioedema Partnering 2007-2013 [Published Individual.com - May 21 2013]
Challenges of C1-Inhibitor Concentrate Self-Adm... [Published Sexual Development - May 16 2013]
Natural Urticaria & Angioedema Treatment Review... [Published SBWire - May 15 2013]
Data on MYRBETRIQ (mirabegron) as Treatment for... [Published FinanzNachrichten.de - May 07 2013]
Fresh Frozen Plasma for ACEI-Induced Angioedema [Published Medscape - May 06 2013]
Celgene International Sarl Reports European Med... [Published Individual.com - May 01 2013]
Merck & Co., Inc. and Pfizer enter worldwide co... [Published European Pharmaceutical Review - Apr 30 2013]
Merck & Co., Inc. Joins Pfizer Inc. With $60 Mi... [Published BioSpace - Apr 29 2013]
Merck & Co., Inc. and Pfizer Enter Worldwide Co... [Published BioMedReports - Apr 29 2013]
Health Article - Angioedema (Giant Hives): Over... [Published AARP - Segunda Juventud - Apr 19 2013]
Santarus Stock Climbs Slightly After Submitting... [Published San Diego Business Journal - Apr 18 2013]
Hereditary and acquired angioedemas: rare but p... [Published Medicine Today - Apr 16 2013]
Novartis' ASTERIA II stuy shows omalizumab impr... [Published PharmaBiz - Feb 26 2013]
Dyax Corp. and CVie Therapeutics Announce Partn... [Published EON Health & Medicine - Feb 07 2013]
Dyax Corp. and CVie Therapeutics Announce Partn... [Published Business Wire Health News - Feb 07 2013]
Dyax Corp. and Novellus Biopharma AG Announce P... [Published EON Health & Medicine - Jan 31 2013]
Dyax Corp. and Novellus Biopharma AG Announce P... [Published Business Wire Health News - Jan 31 2013]
Sub-Group Analysis Of Data From Pediatric Patie... [Published PR Newswire: Entertainment & Media - Jan 16 2013]
CSL Behring Launches Its First Co-Pay Assistanc... [Published PR Newswire: Financial Services - Jan 02 2013]
ViroPharma Launches Novel Campaign to Illustrat... [Published PR Newswire: Consumer Technology - Dec 12 2012]
Frédéric Chereau Joins Shire Human Genetic Ther... [Published Shire Pharmaceuticals - Sep 27 2012]